Baird lowered the firm’s price target on Xponential Fitness (XPOF) to $13 from $15 and keeps a Neutral rating on the shares. The firm said Q3 revenue beat, while adjusted EBITDA fell short on lower margin performance.
Baird lowered the firm’s price target on Xponential Fitness (XPOF) to $13 from $15 and keeps a Neutral rating on the shares. The firm said Q3 revenue beat, while adjusted EBITDA fell short on lower margin performance.